Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $71.08, for a total value of $156,376.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Tuesday, June 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.61, for a total value of $155,342.00.
• On Monday, May 12th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $72.06, for a total value of $158,532.00.

Corcept Therapeutics Stock Down 2.2%

Corcept Therapeutics stock traded down $1.62 during mid-day trading on Tuesday, hitting $71.15. 305,092 shares of the company's stock were exchanged, compared to its average volume of 1,184,246. The firm has a market capitalization of $7.54 billion, a P/E ratio of 61.15 and a beta of 0.15. Corcept Therapeutics Incorporated has a fifty-two week low of $31.46 and a fifty-two week high of $117.33. The company's 50 day simple moving average is $72.67 and its 200-day simple moving average is $66.60.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.17. The company had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. Corcept Therapeutics had a net margin of 19.33% and a return on equity of 20.40%. The company's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.25 earnings per share. Research analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Truist Financial set a $135.00 price objective on Corcept Therapeutics in a research note on Tuesday, May 6th. Wall Street Zen lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright lowered their price objective on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, Piper Sandler raised their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research note on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $138.25.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds have recently modified their holdings of the company. Brooklyn Investment Group lifted its position in Corcept Therapeutics by 99.5% in the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 186 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Corcept Therapeutics by 102.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 620 shares of the biotechnology company's stock valued at $71,000 after buying an additional 313 shares during the period. Covestor Ltd lifted its holdings in shares of Corcept Therapeutics by 1,741.2% during the 1st quarter. Covestor Ltd now owns 626 shares of the biotechnology company's stock valued at $72,000 after buying an additional 592 shares during the period. IFP Advisors Inc lifted its holdings in shares of Corcept Therapeutics by 1,150.8% during the 1st quarter. IFP Advisors Inc now owns 738 shares of the biotechnology company's stock valued at $84,000 after buying an additional 679 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in shares of Corcept Therapeutics during the 4th quarter valued at $40,000. Hedge funds and other institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.